Takeda Pharmaceuticals America and Affymax have entered into a supply agreement for sourcing and supply of Omontys (peginesatide) Injection to Fresenius Medical Care North America and certain affiliates. Omontys, a once-monthly erythropoiesis-stimulating agent (ESA) for anemia, will now be available to dialysis patients with chronic kidney disease (CKD) in the U.S.
 
The agreement, which ends in April 2013, allows Fresenius Medical Care North America to purchase Omontys for use in U.S. centers within its organization and provides for discounts and rebates on the product, subject to certain requirements. Financial terms were not disclosed.
 
“We are excited to partner with Fresenius Medical Care North America, one of the world’s leading dialysis providers, to offer a new therapeutic option for the treatment of anemia in its chronic kidney disease patients on dialysis,” said Nicole Mowad-Nassar, vice president, marketing at Takeda.
 
“As a biotechnology company dedicated to advancing new therapies for renal diseases, Affymax shares Fresenius Medical Care North America’s commitment to innovation,” said John Orwin, chief executive officer of Affymax. “We are very pleased to support Fresenius Medical Care in these efforts to integrate Omontys into its organization and to collaborate with them moving forward.”